- Home
- HURA vs ZNTL Comparison
HURA vs ZNTL Comparison
Compare HURA & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HURA | ZNTL |
|---|---|---|
| Founded | 2009 | 2014 |
| Country | United States | United States |
| Employees | 19 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 87.5M | 156.7M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | HURA | ZNTL |
|---|---|---|
| Price | $2.12 | $2.71 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $10.00 | $6.60 |
| AVG Volume (30 Days) | ★ 944.7K | 695.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 47.87 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $67,425,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.41 | $1.01 |
| 52 Week High | $4.41 | $3.95 |
Technical Indicators
Market Signals| Indicator | HURA | ZNTL |
|---|---|---|
| Relative Strength Index (RSI) | 72.34 | 54.87 |
| Support Level | $1.56 | $1.29 |
| Resistance Level | $2.16 | $3.95 |
| Average True Range (ATR) | 0.23 | 0.22 |
| MACD | 0.04 | 0.04 |
| Stochastic Oscillator | 95.29 | 51.67 |
Price Performance
Historical ComparisonAbout HURA TuHURA Biosciences Inc.
TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.